Asana BioSciences, LLC today announced that it recently completed relocating its offices from Bridgewater, New Jersey to the Princeton Pike Corporate Center in Lawrenceville, New Jersey. The company cites the need for larger office space to accommodate its growing business needs.
“This move was necessary to further our vision of building an oncology-focused biopharmaceutical company,” said Sandeep Gupta, Ph.D., president and chief executive officer of Asana BioSciences. “As we continue to expand and grow, our new Princeton area location makes it ideal for us to attract key scientific and medical talent within the Central New Jersey and Philadelphia life sciences corridor.”
Asana continues to advance its portfolio of differentiated targeted therapies to help address major unmet medical needs, including a novel CYP17 inhibitor for prostate cancer and a dual Syk/JAK inhibitor for non-Hodgkin’s lymphoma that are in phase I/II clinical trials. Over the past year, it has been adding key talent to its team, including the appointment of a chief medical officer and expansion of its scientific advisory board.
About Asana BioSciences
Asana BioSciences, LLC, an independent member of The Amneal Alliance of companies, is a research and development company based in Lawrenceville, New Jersey, specializing in the discovery and development of novel drug candidates including an antibody-drug conjugate. Asana’s portfolio consists of multiple early-stage development candidates in a variety of therapeutic areas, including oncology, pain and inflammation, among others. www.asanabiosciences.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160823006147/en/Business Wire
Last updated on: 23/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.